| Molecular Formula | C20H28N6O3 |
| Molar Mass | 400.47 |
| Density | 1.30±0.1 g/cm3(Predicted) |
| Boling Point | 652.3±65.0 °C(Predicted) |
| Appearance | White solid |
| pKa | 13.95±0.10(Predicted) |
| Storage Condition | Sealed in dry,Store in freezer, under -20°C |
| In vitro study | CVT-313 (Cdk2 Inhibitor III) has been shown to inhibit other kinases, but at much higher IC 50 values, i.e., CDK1 (IC 50 =4.2 μM), CDK4 D1 (IC 50 =215 μM), and MAPK/PKA/PKC (IC 50 >1.25 mM), compared to CDK2 (IC 50 =0.5 μM). CVT-313 has been shown to have profound effects on cell proliferation at concentrations of 5-20 μM. CVT-313 is a potent CDK2 inhibitor, which is identified from a purine analog library with an IC 50 of 0.5 μM in vitro. Inhibition is competitive with respect to ATP (K i =95 nM), and selective CVT-313 has no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 is required for half-maximal inhibition of the enzyme activity. Using normal and tumor human/murine cell lines, the effects of CVT-313 on cell proliferation is measured. The IC 50 for growth inhibition ranged from 1.25 to 20 μM. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.497 ml | 12.485 ml | 24.971 ml |
| 5 mM | 0.499 ml | 2.497 ml | 4.994 ml |
| 10 mM | 0.25 ml | 1.249 ml | 2.497 ml |
| 5 mM | 0.05 ml | 0.25 ml | 0.499 ml |
| biological activity | CVT-313 is a effective CDK2 inhibitor with an IC50 value of 0.5 μM in vitro. It has no effect on other unrelated, ATP-dependent serine/threonine kinases. |
| target | TargetValue CDK2 (Cell-free say) 0.5 μM |
| Target | Value |
| CDK2 (Cell-free assay) | <0.5 μM |
| in vitro study | CVT-313 (Cdk2 Inhibitor III) has been shown to inhibit other kinases, but at much higher IC 50 values, I. e., CDK1 (IC 50=4.2 μM), CDK4 D1 (IC 50=215 μ m), and MAPK/PKA/PKC (IC 50 >1.25 mM), compared to CDK2 (IC 50=0.5 μ m). CVT-313 has been shown to have profound effects on cell proliferation at concentrations of 5-20 μ m. CVT-313 is a potent CDK2 inhibitor, which is identified from a purine analog library with an IC 50 of 0.5 μM in vitro. Inhibition is competitive with respect to ATP (K I = 95 nM), and selective CVT-313 has no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, A 8.5- and 430-fold higher concentration of CVT-313 is required for half-maximal inhibition of the enzyme activity. using normal and tumour human/murine cell lines, the effects of CVT-313 on cell proliferation is measured. the IC 50 for growth inhibition range from 1.25 to 20 μ m. |